201 related articles for article (PubMed ID: 31707428)
1. Variations in radioiodine ablation: decision-making after total thyroidectomy.
Maas O; Forrer F; Maas M; Panje CM; Blautzik J; Brühlmeier M; Engel-Bicik I; Giovanella L; Haldemann A; Kamel ME; Kneifel S; Rottenburger C; Schaefer N; Walter MA; Weidner S; Putora PM
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):554-560. PubMed ID: 31707428
[TBL] [Abstract][Full Text] [Related]
2. Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.
Forrer F; Fischer GF; Maas O; Giovanella L; Hoffmann M; Iakovou I; Luster M; Mihailovic J; Petranovic Ovčariček P; Vrachimis A; Zerdoud S; Putora PM
Oncology; 2022; 100(2):74-81. PubMed ID: 34788758
[TBL] [Abstract][Full Text] [Related]
3. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer.
Abe K; Ishizaki U; Ono T; Horiuchi K; Kanaya K; Sakai S; Okamoto T
Ann Nucl Med; 2020 Feb; 34(2):144-151. PubMed ID: 31834567
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.
Tu J; Wang S; Huo Z; Lin Y; Li X; Wang S
Radiother Oncol; 2014 Jan; 110(1):25-30. PubMed ID: 24485353
[TBL] [Abstract][Full Text] [Related]
5. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer.
Handkiewicz-Junak D; Gawlik T; Rozkosz J; Puch Z; Michalik B; Gubala E; Krajewska J; Kluczewska A; Jarzab B
Eur J Endocrinol; 2015 Dec; 173(6):873-81. PubMed ID: 26423095
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose.
Campennì A; Amato E; Laudicella R; Alibrandi A; Cardile D; Pignata SA; Trimarchi F; Ruggeri RM; Auditore L; Baldari S
Endocrine; 2019 Jul; 65(1):132-137. PubMed ID: 30875058
[TBL] [Abstract][Full Text] [Related]
9. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States.
Wang TS; Cheung K; Mehta P; Roman SA; Walker HD; Sosa JA
J Clin Endocrinol Metab; 2010 Apr; 95(4):1672-80. PubMed ID: 20139234
[TBL] [Abstract][Full Text] [Related]
10. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
[TBL] [Abstract][Full Text] [Related]
11. Low- and high-dose radioiodine ablation for low-/intermediate-risk differentiated thyroid cancer in China: Large randomized clinical trial.
Dong P; Wang L; Qu Y; Huang R; Li L
Head Neck; 2021 Apr; 43(4):1311-1320. PubMed ID: 33470031
[TBL] [Abstract][Full Text] [Related]
12. High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal.
Bartenstein P; Calabuig EC; Maini CL; Mazzarotto R; Muros de Fuentes MA; Petrich T; Rodrigues FJ; Vallejo Casas JA; Vianello F; Basso M; Balaguer MG; Haug A; Monari F; Vaňó RS; Sciuto R; Magner J
Thyroid; 2014 Mar; 24(3):480-7. PubMed ID: 24040896
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine ablation in thyroid cancer patients: renal function and external radiation dose rate at discharge according to patient preparation.
Han YH; Jeong HJ; Sohn MH; Lee SY; Lim ST
Q J Nucl Med Mol Imaging; 2020 Mar; 64(1):124-130. PubMed ID: 29521481
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
15. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
16. Acknowledging gray areas: 2015 vs. 2009 American Thyroid Association differentiated thyroid cancer guidelines on ablating putatively low-intermediate-risk patients.
Frangos S; Iakovou IP; Marlowe RJ; Eftychiou N; Patsali L; Vanezi A; Savva A; Mpalaris V; Giannoula EI
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):185-189. PubMed ID: 27557846
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine.
Mujammami M; Hier MP; Payne RJ; Rochon L; Tamilia M
Thyroid; 2016 Jul; 26(7):951-8. PubMed ID: 27150203
[TBL] [Abstract][Full Text] [Related]
18. Controversies in Radioiodine Treatment of Low- and Intermediate-risk Thyroid Cancer.
Eilsberger F; Verburg FA
Clin Oncol (R Coll Radiol); 2021 Feb; 33(2):68-74. PubMed ID: 33250287
[TBL] [Abstract][Full Text] [Related]
19. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed?
Haugen BR
Cancer; 2017 Feb; 123(3):372-381. PubMed ID: 27741354
[TBL] [Abstract][Full Text] [Related]
20. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
